Titre:
  • Copy number aberration analysis to predict response to neoadjuvant antiHER2 therapy: results from the NeoALTTO phase III clinical trial
Auteur:Venet, David; Rediti, Mattia; Maetens, Marion M.; Fumagalli, Debora; Brown, David Norman; Majjaj, Samira; Salgado, Roberto; Pusztai, Lajos; Harbeck, Nadia; El-Abed, Sarra; Wang, Yingbo; Saura, Cristina; Gomez, H.L.; Semiglazov, Vladimir Fedorovich; Azambuja, Evandro; Huober, J.; Nuciforo, Paolo Giovanni; Di Cosimo, Serena; Piccart-Gebhart, Martine; Loi, Sherene; Rothé, Françoise; Sotiriou, Christos
Informations sur la publication:Clinical cancer research, 27, 20, page (5607-5618)
Statut de publication:Publié, 2021-10-01
Sujet CREF:Cancérologie
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1078-0432
info:doi/10.1158/1078-0432.CCR-21-1317
info:scp/85117405703
info:pmid/34321278